Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.

MLA

Jering, Karola S., et al. “Prospective ARNI vs. ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.” European Journal of Heart Failure, vol. 23, no. 6, June 2021, pp. 1040–48. EBSCOhost, https://doi.org/10.1002/ejhf.2191.

APA

Jering, K. S., Claggett, B., Pfeffer, M. A., Granger, C., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D., McMurray, J. J. V., Rouleau, J., Solomon, S. D., Steg, P. G., Meer, P., Wernsing, M., Carter, K., Guo, W., Zhou, Y., Lefkowitz, M., Gong, J., & Wang, Y. (2021). Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. European Journal of Heart Failure, 23(6), 1040–1048. https://doi.org/10.1002/ejhf.2191

Chicago

Jering, Karola S., Brian Claggett, Marc A. Pfeffer, Christopher Granger, Lars Køber, Eldrin F. Lewis, Aldo P. Maggioni, et al. 2021. “Prospective ARNI vs. ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.” European Journal of Heart Failure 23 (6): 1040–48. doi:10.1002/ejhf.2191.